BioLife Solutions, Inc. (NASDAQ:BLFS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have been given a consensus recommendation of “Moderate Buy” by the five ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $32.00.

A number of equities research analysts have issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, January 21st. Zacks Research upgraded shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. UBS Group reissued a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. Northland Securities set a $34.00 target price on shares of BioLife Solutions in a research note on Monday, January 5th. Finally, Wall Street Zen cut BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Sunday, November 30th.

Insider Activity at BioLife Solutions

In other news, CFO Troy Wichterman sold 30,000 shares of BioLife Solutions stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $25.72, for a total transaction of $771,600.00. Following the sale, the chief financial officer owned 152,769 shares in the company, valued at $3,929,218.68. This trade represents a 16.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Amy Duross sold 2,000 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $27.00, for a total transaction of $54,000.00. Following the transaction, the director directly owned 22,687 shares in the company, valued at approximately $612,549. The trade was a 8.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 42,005 shares of company stock worth $1,080,100 over the last three months. 2.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BioLife Solutions

A number of large investors have recently added to or reduced their stakes in BLFS. Jacobs Levy Equity Management Inc. acquired a new position in BioLife Solutions in the 1st quarter worth $283,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of BioLife Solutions by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider’s stock valued at $489,000 after acquiring an additional 914 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of BioLife Solutions during the first quarter worth about $1,091,000. Strs Ohio acquired a new position in shares of BioLife Solutions in the first quarter worth about $153,000. Finally, AlphaQuest LLC acquired a new position in shares of BioLife Solutions in the second quarter worth about $149,000. 93.24% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Stock Down 0.6%

NASDAQ:BLFS opened at $23.09 on Friday. The company has a market cap of $1.11 billion, a P/E ratio of -329.81 and a beta of 1.92. The firm’s 50 day moving average is $24.03 and its two-hundred day moving average is $25.19. BioLife Solutions has a fifty-two week low of $19.10 and a fifty-two week high of $29.62.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.